Study summary

A CD19 antibody added to R2 cut the risk of progression by more than half

inMIND trial · 548 people, phase 3 · Published December 2025, The Lancet; FDA approved 2025

What was tested

Tafasitamab, an antibody aimed at the CD19 protein on B cells, added to lenalidomide and rituximab, against placebo plus the same drugs, for relapsed or refractory follicular lymphoma.

What they found

• Median progression-free survival was 22.4 vs 13.9 months (hazard ratio 0.43).
• Neutropenia (49% vs 45%) and diarrhea (38% vs 28%) were the most common side effects.

What it means

A second way to strengthen R2 at relapse, borrowed from large B-cell lymphoma, where tafasitamab was first approved.